Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GE Healthcare Set To Launch First Global Ubiquitous Health R&D Center In Korea

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Aiming to gain momentum from South Korea's push to enhance the national healthcare industry, GE Healthcare is gearing up to open its first global ubiquitous health research and development center in Asia

You may also be interested in...



Medical Device Companies Come Up With Creative Solutions To Increase Access To Rural Communities In Asia

HONG KONG - A little less than two years ago, multinational conglomerate GE Healthcare said it would spend up to $6 billion in healthcare innovation through a program dubbed "Healthymagination.

Medical Device Companies Come Up With Creative Solutions To Increase Access To Rural Communities In Asia

HONG KONG - A little less than two years ago, multinational conglomerate GE Healthcare said it would spend up to $6 billion in healthcare innovation through a program dubbed "Healthymagination.

J&J's Bid For Crucell Hits Speed Bump With Shipment Suspension At Korean Vaccine Plant

Johnson & Johnson's acquisition offer for Crucell appears to be on track despite news that the Dutch biotech firm suspended all shipments of hepatitis B vaccine Hepavax-Gene and childhood pediatric vaccine Quinvaxem due to issues at its Korean unit Berna Biotech Korea.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC073091

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel